Navigation Links
Denali Concrete Management Inc. Announces the Commencement of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study
Date:12/21/2011

CARSON CITY, Nev., Dec. 21, 2011 /PRNewswire/ -- Denali Concrete Management Inc. (OTCBB: DCMG) announced today that it has commenced patient enrollment for a phase 3 clinical study of the safety and efficacy of CF101, daily administered orally, in patients with moderate-to-severe Dry Eye Syndrome. This multi-center clinical trial is conducted in the United States, Europe and Israel. The randomized, double-masked clinical trial will include 231 patients who will be randomized to receive 2 doses of CF101 and Placebo, for a period of 24 weeks.  The primary efficacy endpoint will be complete clearing of corneal staining.

The population suffering from Dry Eye Syndrome is estimated at 49 million people in the seven major markets and is characterized by eye irritation symptoms, blurred and fluctuating vision, tear film instability, increased tear osmolarity and ocular surface epithelial disease. People with Dry Eye Syndrome experience constant ocular discomfort and a decrease in visual function; in severe cases, Dry Eye Syndrome may result in deterioration of vision.

Dr. Pnina Fishman, the Company's interim CEO stated, "We are very pleased with the initiation of enrollment to the Dry Eye Syndrome phase 3 study. The positive data from the previous phase 2 study as well as the excellent safety profile of CF101 indicates the potential of this innovative oral drug for the treatment of Dry Eye Syndrome."

In addition, the Company announces today that by action of the Board of Directors and the shareholders, it has changed its name to OphthaliX Inc.

About CF101

CF101, an A3 adenosine receptor agonist, is a novel, first in class, small molecule, orally bioavailable drug with a proven efficacy in Phase 2 clinical studies and an excellent safety profile. CF101 is currently developed for ophthalmic indications including Dry Eye Syndrome (Phase 3), Glaucoma (Phase 2) and Uveitis. CF101 is also developed for the trea
'/>"/>

SOURCE Denali Concrete Management Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share
2. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
3. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
4. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
5. Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
6. U.S. Preventive Medicine Acquires Specialty Disease Management
7. Cellectar Expands Clinical Management Team
8. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
9. New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
10. Lilly Receives NCQA Design Certification for Depression Care Management Program
11. Micromet Announces Changes in Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... , May 24, 2013 In accordance with ... and Rule 14e-1 of the United States Exchange Act, Echo ... original offer for Elan Corporation (NYSE: ELN). Background ... ("Royalty Pharma") made an offer for the entire of the ... plc ("Elan") (the "Original Offer").  On 20 ...
(Date:5/23/2013)... 2013 3SBio Inc. (NASDAQ: ... China -based biotechnology company focused ... announced today that, at an extraordinary general meeting ... in favor of the proposal to authorize and ... merger dated February 8, 2013, among Decade Sunshine ...
(Date:5/23/2013)... , May 23, 2013 Amgen (NASDAQ: ... th Annual  Healthcare Conference on Thursday, May 30, 2013, ... , beginning at 9:20 a.m. Eastern Daylight Time. ... Amgen, will present at the conference. Live audio of the ... website, www.amgen.com , under Investors. A replay of the ...
Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 93SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3
(Date:5/25/2013)... 25, 2013 Studies from Johns Hopkins ... carrying excessive weight and their inability to get adequate ... losing weight can naturally relieve many symptoms. , ... in sleep quality was significantly associated with overall weight ... study dated November 6th, 2012, researchers monitored 77 ...
(Date:5/25/2013)... Absolute Surgical Specialists, serving Sun City Center ... businesses throughout the country participating in Shop Local for a ... nationwide event as he understands what military families go through ... He said, “I wanted to give something back, as I ... live here too.” , Shop Local for a Cause has ...
(Date:5/25/2013)... York, New York (PRWEB) May 25, 2013 ... who allegedly suffered serious, life-threatening episodes of internal bleeding while ... litigation underway in U.S. District Court, Southern District of Illinois, ... the Court’s website, 818 Pradaxa side effect claims had ... 2013. That’s up from 705 claims reported by the ...
(Date:5/25/2013)... By working diligently for months on ... of the 2012 Lamborghini Aventador into their well-built fitments ... in the list of vehicles lined by SizeItUp for ... set to thrill automobile lovers in the year 2013. ... looks, the 2012 Lamborghini Aventador comes with extraordinarily spacious ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 According ... Emergency Management Market, 2013–2018", published by MarketsandMarkets is ... a CARC of 5.54% which analyzes and studies ... North America, Europe, Asia, and Rest of the ... Market Data Tables , 87 Figures ...
Breaking Medicine News(10 mins):Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep 2Health News:Dr. Craig Amshel of Absolute Surgical Specialists Offering Bowel Prep During the Shop Local for a Cause Event 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3Health News:Rim Fitments Provider SizeItUp Launches The Database Integration For The 2012 Lamborghini Aventador 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 3Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 4
... Garca Navarro, a researcher at the School of Pharmacy at ... colon and liver cancer. The new treatment has shown ... ,This discovery is the principal result of her doctoral ... Cancer Cells of the Colon, which was subsidized by the ...
... who suffer bouts of nausea and vomiting during their pregnancies ... but it seems that going through morning sickness is a ... who have conducted a new study and found that women ... risk of developing breast cancer later in life than expecting ...
... shown a decline, thanks to the comprehensive program in 2002, ... 2006 report shows a decline in the smoking rate ... past year, smoking decreased among men (from 22.5% to 19.9%) ... followed a year-long ad campaign aimed at prompting more smokers ...
... cause effects ranging from learning and memory capabilities to ... of St.Jude Childrens Research hospital . ... factora molecule that binds to a section of DNA near ... protein for which it codes. CREB activates genes in response ...
... who allegedly tried to get his 15-year-old son into the record ... said the accusation was a ploy by his detractors to defame ... a video recording of his son Dhileepan Raj, a tenth standard ... other doctors in the hope of making his son attain the ...
... occurs as a solid tumor in the abdomen, but ... the network of the body's sympathetic nervous system. ... neuroblastoma is a special case, accounting for 7 percent ... cancer deaths. ,Neuroblastoma is what physicians ...
Cached Medicine News:Health News:Novel Treatment Beneficial for Colon and Liver Cancer 2Health News:Morning Sickness may Signify Lower Breast Cancer Risk 2Health News:Morning Sickness may Signify Lower Breast Cancer Risk 3Health News:New York Records Decline in Smoking Rate 2Health News:Research Studies on Molecular Switches of Gene 2Health News:The Bottleneck in Neuroblastoma 2
Jewelers forceps. Insulated....
Semkin forceps with stops. Insulated....
Gerald bayonet forceps. Insulated....
Cushing forceps. Insulated....
Medicine Products: